Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome
Cancer Immunology, Immunotherapy · 2023-12 · 72 (12) · 4261-4278
DOI: 10.1007/s00262-023-03562-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 05.11.2023. Verfasst von Aliva Prity Minz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, 751023, India. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Carcinoma, Pancreatic Ductal, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pancreatic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A combination of chemotherapy with immunotherapy has been proposed to have better clinical outcomes in Pancreatic Ductal Adenocarcinoma (PDAC). On the other hand, chemotherapeutics is known to have certain unwanted effects on the tumor microenvironment that may mask the expected beneficial effects of immunotherapy. Here, we have investigated the effect of gemcitabine (GEM), on two immune checkpoint proteins (PD-L1 and PD-L2) expression in cancer associated fibroblasts (CAFs) and pancreatic cancer cells (PCCs). Findings of in vitro studies conducted by using in-culture activated mouse pancreatic stellate cells (mPSCs) and human PDAC patients derived CAFs demonstrated that GEM significantly induces PD-L1 and PD-L2 expression in these cells. Moreover, GEM induced phosphorylation of STAT1 and production of multiple known PD-L1-inducing secretory proteins including IFN-γ in CAFs. Upregulation of PD-L1 in PSCs/CAFs upon GEM treatment caused T cell inactivation and apoptosis in vitro. Importantly, Statins suppressed GEM-induced PD-L1 expression both in CAFs and PCCs while abrogating the inactivation of T-cells caused by GEM-treated PSCs/CAFs. Finally, in an immunocompetent syngeneic orthotopic mouse pancreatic tumor model, simvastatin and GEM combination therapy significantly reduced intra-tumor PD-L1 expression and noticeably reduced the overall tumor burden and metastasis incidence. Together, the findings of this study have provided experimental evidence that illustrates potential unwanted side effects of GEM that could hamper the effectiveness of this drug as mono and/or combination therapy. At the same time the findings also suggest use of statins along with GEM will help in overcoming these shortcomings and warrant further clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, 751023, India.
- Regional Centre for Biotechnology, Faridabad, Haryana, India.
- CV Raman Global University, Bhubaneswar, Odisha, India.
- Department of General Surgery, All India Institute of Medical Sciences, Bhubaneswar, India.
- Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, 751023, India. senapati@ils.res.in.
Zitieren
APA
Minz, A. P., Mohapatra, D., Dutta, M., Sethi, M., Parida, D., Mohapatra, A. P., Mishra, S., Kar, S., Sasmal, P. K., & Senapati, S. (2023). Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome. Cancer Immunology, Immunotherapy, 72(12), 4261-4278. https://doi.org/10.1007/s00262-023-03562-9
Vancouver
Minz AP, Mohapatra D, Dutta M, Sethi M, Parida D, Mohapatra AP, et al. Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome. Cancer Immunology, Immunotherapy. 2023;72(12):4261-4278. doi:10.1007/s00262-023-03562-9
BibTeX
@article{Minz2023,
author = {Minz, Aliva Prity and Mohapatra, Debasish and Dutta, Madhuri and Sethi, Manisha and Parida, Deepti and Mohapatra, Amlan Priyadarshee and Mishra, Swayambara and Kar, Salona and Sasmal, Prakash K and Senapati, Shantibhusan},
title = {Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {12},
pages = {4261--4278},
doi = {10.1007/s00262-023-03562-9}
}
EUVIMED